Liposome-supported peritoneal dialysis in the treatment of severe hyperammonemia: An investigation on potential interactions

Peritoneal dialysis (PD) performed with transmembrane pH-gradient liposomes was reported to efficiently remove ammonia from the body, representing a promising alternative to current standard-of-care for patients with severe hepatic encephalopathy. In this study, we further characterized the properti...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of controlled release Vol. 278; pp. 57 - 65
Main Authors:	Giacalone, Giovanna, Matoori, Simon, Agostoni, Valentina, Forster, Vincent, Kabbaj, Meriam, Eggenschwiler, Sarah, Lussi, Martin, De Gottardi, Andrea, Zamboni, Nicola, Leroux, Jean-Christophe
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 28-05-2018
Subjects:	Acute-on-chronic liver failure Chronic kidney disease Hyperammonemia Liposomes Peritoneal dialysis Acute-on-chronic liver failure Chronic kidney disease Liposomes Peritoneal dialysis Hyperammonemia
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Peritoneal dialysis (PD) performed with transmembrane pH-gradient liposomes was reported to efficiently remove ammonia from the body, representing a promising alternative to current standard-of-care for patients with severe hepatic encephalopathy. In this study, we further characterized the properties of liposome-supported peritoneal dialysis (LSPD) by 1) assessing its in-use stability in the presence of ascitic fluids from liver-disease patients; 2) investigating its interactions with drugs that are commonly administered to acute-on-chronic liver failure patients; and 3) analyzing the in vivo extraction profile of LSPD. We found that LSPD fluid maintained its in vitro ammonia uptake capability when combined with ascitic fluids. The co-incubation of selected drugs (e.g., beta-blockers, antibiotics, diuretics) with LSPD fluids and ammonia resulted in limited interaction effects for most compounds except for two fluoroquinolones and propranolol. However, considering the experimental set-up, these results should be interpreted with caution and confirmatory drug-drug interaction studies in a clinical setting will be required. Finally, metabolite-mapping analysis on dialysates of LSPD-treated rats revealed that the liposomes did not remove important metabolites more than a conventional PD fluid. Overall, these findings confirm that LSPD is a potentially safe and effective approach for treating hyperammonemic crises in the context of acute-on-chronic liver failure. [Display omitted]
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0168-3659 1873-4995
DOI:	10.1016/j.jconrel.2018.03.030